Latest Breaking News On - Renal medicine - Page 1 : comparemela.com

How Can Cardiovascular Risk Be Reduced in Kidney Dialysis?

The experimental IL-6 inhibitor clazakizumab improves key inflammation markers in one study, whereas another shows lower risks with home hemodialysis vs peritoneal dialysis.

United statesStanford universityUniversity of cincinnatiPeter stenvinkelGlenn chertowSilvi shahDivision of nephrologyDivision of renal medicine at karolinska institutetStanford university school of medicineEuropean renal association congressEuropean renal associationStanford university schoolAlbumin improvements calledRenal medicineKarolinska institutetMedscape medical

Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024

Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSan carlosUniversity of illinoisSangeeta bhoradeAli zarrinparElliot aguilarHossein tabrizianiZahraa hajjiriMilagros samaniego picotaSuphamai bunnapradistClinical laboratory improvement amendmentsUniversity of florida healthUmass memorial health careUmass chan school of medicineAmerican transplant congressUniversity of florida college medicine

Invizius s Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study

/PRNewswire/ Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, announces that eight.

United kingdomGlasgow cityDuha ilyasSandip mitraLeonard ebahMagnus nicolsonIlyas duhaProfessor of renal medicine at manchester universityCare researchManchester universityPrnewswire invizius limitedManchester clinical research facilityNational institute for healthAcute kidney injuryNational institutePriming solution

Invizius s Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study

Study demonstrated safety and tolerability of H-Guard®, a second generation complement regulator, designed to address serious immune system-driven complications of dialysis.Encouraging biomarker data positions H-Guard for upcoming Acute Kidney Injury (AKI) trial focused on reducing complement mediated renal tubu.

United kingdomSandip mitraDuha ilyasIlyas duhaMagnus nicolsonLeonard ebahProfessor of renal medicine at manchester universityCare researchManchester clinical research facilityNational institute for healthInvizius limitedManchester universityAcute kidney injuryContinuous renal replacement therapyNational institutePriming solution

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Richard philipsonJonathan barrattShikha wadhwaniRichard lafayetteNorthwestern universityEuropean renal associationRenal medicine at leicester universityChief medical officerPoster presentationFocused oral roomClinical markersIga nephropathyRenal medicineFull prescribingPrimary immunoglobulin